Peanut Allergy Market Detailed Industry Report Analysis 2025-2034

Introduction
Peanut allergy is one of the most common and potentially life-threatening food allergies, especially in children. It is characterized by an abnormal immune response to peanut proteins, which can trigger mild symptoms such as hives and digestive distress or severe, life-threatening anaphylaxis. Unlike other childhood food allergies, peanut allergy often persists into adulthood, creating a lifelong burden for patients and caregivers.

For decades, management focused exclusively on strict peanut avoidance and emergency epinephrine administration. However, accidental exposures remained frequent, and no curative therapies existed. This changed with the approval of the first oral immunotherapy (OIT) in 2020, which marked a paradigm shift. The growing pipeline of epicutaneous immunotherapies, sublingual therapies, biologics (anti-IgE monoclonals), and microbiome-modulating treatments is reshaping the landscape.
In 2024, the global peanut allergy market is valued at USD 1.65 billion and is projected to reach USD 4.12 billion by 2034, growing at a robust CAGR of 9.4% (2025-2034).

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71326

Market Overview: Key Highlights
• Market Size (2024): USD 1.65 Billion
• Forecasted Market Size (2034): USD 4.12 Billion
• CAGR (2025-2034): 9.4%
• Largest Region (2024): North America (~49% share)
• Fastest-Growing Region: Asia-Pacific (~10.2% CAGR)
• Top Therapies: Oral immunotherapy (OIT), epicutaneous immunotherapy (EPIT), sublingual immunotherapy (SLIT), biologics (omalizumab, dupilumab, pipeline agents)

Growth Drivers: Rising prevalence of peanut allergy, FDA/EMA approvals of novel therapies, expansion of clinical trial activity, and strong advocacy from patient organizations.
Challenges: High therapy cost, adherence issues with OIT, limited access in emerging markets, and variability in patient response.

Segmentation Analysis
By Drug Class
• Oral Immunotherapy (OIT): Palforzia (first FDA-approved OIT), plus pipeline OIT agents under development.
• Epicutaneous Immunotherapy (EPIT): Viaskin Peanut (DBV Technologies) under late-stage trials, delivering allergens via skin patches.
• Sublingual Immunotherapy (SLIT): Investigational therapies with growing pediatric trial data.
• Biologics: Omalizumab (anti-IgE, approved for multiple allergic conditions), dupilumab, and emerging monoclonals targeting immune pathways.
• Emergency treatments: Epinephrine auto-injectors (EpiPen, Auvi-Q, generics) remain vital for acute management.

By Therapy Type
• Monotherapy (e.g., OIT alone, biologic alone)
• Combination therapy (e.g., OIT + omalizumab to improve safety and efficacy)

By Technology
• Immunotherapy platforms: Oral, sublingual, epicutaneous delivery
• Biologic monoclonal antibody therapies
• Digital adherence tools (apps, wearable sensors for allergen exposure tracking)

By End Use
• Allergy & immunology specialty clinics
• Pediatric hospitals
• Retail & specialty pharmacies (epinephrine distribution)
• Academic & research centers (clinical trial hubs)

By Application
• Children & adolescents (dominant segment) - highest prevalence and strongest therapy uptake
• Adults - fewer options but increasing inclusion in biologic and immunotherapy studies

Summary:
Children and adolescents represent the largest treatment group, reflecting high prevalence and earlier intervention. OIT leads current revenues, but biologics and EPIT are expected to see the fastest growth as safer, more convenient alternatives.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71326/peanut-allergy-market

Regional Analysis
North America
• Largest market (~49% share), led by the U.S., where Palforzia has been commercialized and clinical trial activity is robust.
• Strong payer frameworks, high physician awareness, and advocacy organizations such as FARE (Food Allergy Research & Education) drive adoption.
• Widespread use of epinephrine auto-injectors complements the therapy market.
Europe
• EMA approvals of OIT and strong clinical research infrastructure support growth.
• The UK, Germany, and France lead adoption, with rising patient registries improving real-world evidence.
• Price negotiations and reimbursement models influence biologic and immunotherapy rollout speed.
Asia-Pacific
• Fastest-growing region (~10.2% CAGR) due to rising prevalence, urbanization, and greater recognition of allergic disorders.
• Japan and South Korea advancing immunotherapy adoption; China and India expanding diagnostic and therapeutic infrastructure.
• Market growth supported by improving insurance access and patient education initiatives.
Middle East & Africa
• GCC countries investing in allergy treatment centers and biologic imports.
• Broader Africa limited to avoidance strategies and epinephrine use due to infrastructure and affordability challenges.
Latin America
• Brazil, Mexico, and Argentina lead demand, with gradual expansion of immunotherapy clinical trials.
• Increasing partnerships between global pharma and local hospitals driving accessibility.

Summary:
North America and Europe dominate today's revenues, but Asia-Pacific is the fastest-growing region, driven by healthcare modernization, allergy awareness campaigns, and early immunotherapy adoption.

Market Dynamics
Key Growth Drivers
1. Rising Peanut Allergy Prevalence - Affecting millions worldwide, with higher incidence in children.
2. First FDA & EMA Approvals - Palforzia's commercialization has validated OIT as a therapeutic option.
3. Strong Pipeline - EPIT, SLIT, and biologics expected to expand choice and safety.
4. Patient Advocacy - Food allergy groups pushing for earlier diagnosis and broader therapy access.
5. Global Clinical Trial Expansion - Increasing recruitment in Asia and Latin America.

Key Challenges
1. Adherence Barriers - OIT requires strict dosing schedules and carries risk of adverse reactions.
2. High Costs - Biologics and long-term immunotherapies remain expensive.
3. Limited Access - Emerging markets still rely primarily on avoidance and emergency epinephrine.
4. Variable Response - Not all patients achieve sustained desensitization.

Latest Market Trends
1. Biologic Integration - Omalizumab and dupilumab used alongside OIT to reduce risk.
2. Patient-Centric Care Models - Multidisciplinary clinics integrating allergists, pediatricians, and psychologists.
3. Digital Health Support - Apps for dosing reminders, allergy education, and emergency response.
4. Regulatory Incentives - FDA and EMA fast-track pathways for pediatric allergy drugs.
5. Next-Generation Therapies - Microbiome-based and DNA vaccine approaches entering early trials.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71738

Competitor Analysis
Major Players
• Aimmune Therapeutics (Nestlé Health Science) - Palforzia (oral immunotherapy)
• DBV Technologies - Viaskin Peanut (epicutaneous patch therapy, late-stage pipeline)
• Regeneron/Sanofi - Dupilumab (IL-4/IL-13 inhibitor, expanding into food allergy trials)
• Novartis AG / Genentech (Roche) - Omalizumab (anti-IgE monoclonal antibody)
• ALK-Abelló - Allergen immunotherapy portfolio development
• Pfizer, Takeda, AstraZeneca - Investing in immunology and allergy pipelines
• Mylan/Viatris, Kaleo, Teva - Epinephrine auto-injectors (EpiPen, generics, Auvi-Q)
Competitive Landscape:
The peanut allergy market is innovation-driven, with a strong pipeline of immunotherapies and biologics complementing established epinephrine products. Nestlé/Aimmune and DBV Technologies are leading in allergen immunotherapy, while Regeneron, Novartis, and Sanofi bring biologic expertise. Strategic partnerships and patient-support programs are central to driving adoption.

Conclusion
The global peanut allergy market is projected to expand from USD 1.65 billion in 2024 to USD 4.12 billion by 2034, at a CAGR of 9.4%.
• North America and Europe dominate current revenues, while Asia-Pacific will see the fastest growth.
• Oral immunotherapy (Palforzia) has established a new standard, with EPIT and biologics set to transform care over the next decade.
• Digital health, patient advocacy, and biosimilar expansion will support global access.
• Combination strategies (OIT + biologics) may improve safety and adherence, widening eligibility.
For stakeholders, opportunities lie in expanding immunotherapy access, reducing therapy costs, and scaling patient-support ecosystems. Companies that combine scientific innovation with affordability and global reach will shape the future of peanut allergy management.

This report is also available in the following languages : Japanese (ピーナッツアレルギー市場), Korean (땅콩 알레르기 시장), Chinese (花生过敏市场), French (Marché des allergies aux arachides), German (Erdnussallergiemarkt), and Italian (Mercato delle allergie alle arachidi), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71326

Our More Reports:

Gastric Cancer Market
https://exactitudeconsultancy.com/reports/71170/gastric-cancer-market

Chronic Myelomonocytic Leukemia Market
https://exactitudeconsultancy.com/reports/71168/chronic-myelomonocytic-leukemia-market

Diffuse Large B-cell Lymphoma Market
https://exactitudeconsultancy.com/reports/71166/diffuse-large-b-cell-lymphoma-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.

https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.